Search research articles
Contact Us
Filters
Showing results (161-170 of 188) with videos related to
Page
of 19
Sort By:
The New England Journal of Medicine
|
October 9, 2016
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
The New England Journal of Medicine
|
April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancer
Edward B Garon, Naiyer A Rizvi, Rina Hui, et al.
Journal for Immunotherapy of Cancer
|
June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Paolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
Neuro-Oncology
|
April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology
|
November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
Julie R Brahmer, Georgina V Long, Omid Hamid, et al.
Journal for Immunotherapy of Cancer
|
October 18, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, et al.
The Lancet. Oncology
|
February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A McArthur, Paul B Chapman, Caroline Robert, et al.
Iscience
|
September 17, 2024
Low booster uptake in cancer patients despite health benefits
Jane C Figueiredo, Julia Levy, So Yung Choi, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 14, 2023
Low booster uptake in cancer patients despite health benefits
Jane C Figueiredo, Julia Levy, So Yung Choi, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 188) with videos related to
Sort By:
Page
of 19
The New England Journal of Medicine
|
October 9, 2016
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
The New England Journal of Medicine
|
April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancer
Edward B Garon, Naiyer A Rizvi, Rina Hui, et al.
Journal for Immunotherapy of Cancer
|
June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Paolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
Neuro-Oncology
|
April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology
|
November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
Julie R Brahmer, Georgina V Long, Omid Hamid, et al.
Journal for Immunotherapy of Cancer
|
October 18, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, et al.
The Lancet. Oncology
|
February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A McArthur, Paul B Chapman, Caroline Robert, et al.
Iscience
|
September 17, 2024
Low booster uptake in cancer patients despite health benefits
Jane C Figueiredo, Julia Levy, So Yung Choi, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 14, 2023
Low booster uptake in cancer patients despite health benefits
Jane C Figueiredo, Julia Levy, So Yung Choi, et al.
Page
of 19